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Preterm birth (PTB) is clinically deﬁned as any delivery which occurs before the completion of 37 weeks of gestation, and is
currently the most important problem in obstetrics. In the United States, PTB accounts for 12-13% of all live births, and, with
the exception of fetuses suﬀering from anomalies, is the primary cause of perinatal mortality. While the risk factors for PTB are
numerous, the single most common cause is intrauterine infection. As there is currently no FDA-approved therapy for infection-
associated PTB, understanding the pathogenesis of preterm labor (PTL) and delivery should be given high priority. The matrix
metalloproteinases (MMPs) are a family of enzymes that have been implicated in normal parturition as well as infection-triggered
rupture of membranes and preterm birth. Several lines of evidence also suggest a role for endothelin-1 (ET-1) in infection-
associated preterm delivery. This paper focuses on the evidence that the MMPs and ET-1 act in the same molecular pathway
in preterm birth.
1.Introduction
Preterm birth (PTB) is deﬁned as any delivery occurring
beforethe completionof37weeks ofgestation,andcurrently
accounts for 12-13% of all births in the United States.
Despite advances that have been made in the ﬁeld of
neonatology and in our understanding of the mechanisms
involved in parturition, the occurrence of PTB has not
declined, and accounts for approximately 5,000 infant deaths
in the United States per year [1]. In 2005, the National
Center for Health Statistics (Centers for Disease Control
and Prevention) reported that there were 522,913 live
preterm births in the United States, corresponding to a
20% increase (from 10.6% to 12.7%) in the number of
women delivering prematurely, when compared to 1990
(http://www.marchofdimes.com/peristats/).
Babies born prematurely are at increased risk of having
low birth weight (<2,500 grams) and of perinatal mortality
[2]. While most deaths occur in babies born before 32 weeks
of gestation, the biggest challenge arises when caring for
those born at less than 28 weeks of gestational age. At this
point, babies are considered to be of very low birth weight
(VLBW), weighing <1,500 grams (3.33lbs), and their organs
are signiﬁcantly less developed than those of those delivered
at a later time. An estimated 6% of preterm babies are born
before the completion of 28 weeks, while 71% are born
between 34 and 36 weeks of gestation, and are referred to as
“late preterm” [2–4].
The single most common cause of spontaneous PTB,
aside from a previous premature delivery, is intrauterine
infection in the mother (40%). Furthermore, the earlier on
in the gestational time period at the time of delivery, the
more likely it is that there is microbial infection in the
amniotic cavity [5]. Seen especially in infants born before
the completion of 34 weeks of gestation, amniotic ﬂuid (AF)
infection is often coupled with a proinﬂammatory response
noted by the presence of cytokines such as tumor necrosis
factor-alpha (TNF-α) and interleukin-6 (IL-6) [5]. High
levels of inﬂammatory cytokines have also been found in
the cerebral spinal ﬂuid of preterm infants, but appear to2 Obstetrics and Gynecology International
be independent of gestational age [6]. Other risk factors
for PTB include cervical or uterine abnormalities, lack of
proper medical care, stress, smoking, and maternal age [1,
7].
In the clinical setting, inhibition of myometrial contrac-
tions (tocolysis) is the focus of therapeutic approaches for
preventing PTB since the contracting uterus is the most
commonly recognized precursor of an early delivery [8].
Magnesium sulfate (MgSO4) is currently the tocolytic agent
of choice, used by approximately 70% of responding medical
personnel, followed by terbutaline (13%), nifedipine (11%),
and indomethacin (6%). Interestingly, none of the drugs
mentioned above have been proven to have a signiﬁcant
eﬀect in adequately delaying gestation or in enhancing
neonatal outcome [9–12].
Currentlyunavailable,atocolyticagentwouldrequirethe
widespread documentation of its eﬃcacy and safety, for both
the mother and fetus. In the United States, and also abroad,
recent guidelines have stressed the importance of the need
to explore the postnatal consequences of infants exposed
to tocolytic agents in utero. It is here that the importance
of nonclinical animal studies becomes evident as they are
needed to investigate the ﬁndings which cannot be ethically,
suﬃciently, and/or safely determined with pediatric clinical
trials [13–15].
2.The Pathway Leadingto PretermBirth
As mentioned previously, maternal infection is one of
the leading causes of PTB, and is the only pathological
process for which there is a direct causal relationship with
prematurity [16]. However, despite a vast accumulation of
humanandanimaldata,theexactpathwaysandmechanisms
leading to this point remain incompletely understood.
While systemic maternal infections such as malaria
and pneumonia can cause PTB, the occurrences of these
infections are minimal in developed countries. Instead,
the majority of infections leading to premature labor is
often those which are intrauterine [17]. Unfortunately, the
diagnosis of such types of infections early on in gestation
is complicated. This can be attributed to the fact that the
most tell-tale clinical signs of infection, which include fever,
tenderness of the uterus, fetal tachycardia, and so forth,
tend to occur late in the process of evolving infection,
and do not present in a large percent of women, despite
evidence that microorganisms are present in the amniotic
cavity [18]. Mothers with infection of the amniotic cav-
ity may not respond as well to treatment with tocolyt-
ics due to the presence of underlying inﬂammation [18,
19].
The most common route by which infection occurs is
via the ascension of microorganisms from the vagina and
cervix through the chorioamniotic membranes and into the
amniotic cavity, where it will eventually cause infection in
the fetus. As a result, a fetal inﬂammatory response may
develop,mostcommonlydenotedbyfunisitis(inﬂammation
of the umbilical cord) which has been associated with the
development of cerebral palsy [17, 20, 21].
The noted presence of bacteria and infection in the
gestationalcompartmentandotherareasofpregnantwomen
have been shown to trigger the immune system via cell
surface recognition molecules such as toll-like receptors
(TLRs) [22] .T L R sa r et r a n s m e m b r a n ep r o t e i n sc a p a b l eo f
recognizing and responding to precise patterns of microbial
components, and initiate the innate immune system in the
host against nonself [23, 24].
Currently, 12 TLRs have been identiﬁed in mammals.
In particular, TLR-2 recognizes Gram-positive bacteria while
TLR-4 recognizes Gram-negative organisms and binds to
lipopolysaccharide (LPS) [25–27]. LPS is a component of
the outer wall of Gram-negative bacteria and is often used
to stimulate an immune response in the animal model.
Except for TLR-3, binding of mammalian TLRs activates the
MyD88- (myeloid diﬀerentiation primary-response genes
88-) dependant pathway, which, in turn, activates the tran-
scription factor nuclear factor-κβ (NF-κβ). NF-κβ has been
implicated in eliciting the expression of proinﬂammatory
genes which play a role in PTB [24, 28, 29].
In humans, the binding of TLR-4 initiates a host
inﬂammatory response involving cytokines such as IL-1
and TNF, thus playing a critical role in the pathogenesis
of infection-associated PTB [30–32]. The inﬂammatory
response is responsible for inducing steps in the latter part
of the parturition cascade, such as decreased prostaglandin
catabolism, functional progesterone withdrawal, increased
expression of proteases, contraction-associated proteins, and
increased uterine contractile activity, ultimately leading to
labor and delivery [22].
3.MatrixMetalloproteinases
During pregnancy, speciﬁc physiological processes such as
cervical ripening, rupture of the fetal membranes, and pla-
centaldetachmentrequiretheremodelingoftheextracellular
matrix (ECM) [33–37]. Rupturing of the membranes is
believed to be the result of the eﬀects of physical forces
whicharelocalizedinareassurroundingthemembranesthat
are made weaker by the degradation of structural collagens
[38]. The matrix metalloproteinases (MMPs) are a family of
enzymes (with more than 20 members identiﬁed) that use
zinc-dependant catalysis to break down the components of
the ECM [39], allowing for the movement of cells and tissue
reorganization in order to support the growing fetus [40].
Several MMPs are constitutively generated by reproductive
tissues, and a ﬂuctuation in the gene expression level of
certain MMPs has been observed during the various stages
of parturition [41].
The ECM of the cervix, fetal membranes, placenta,
and uterus are composed mainly of collagen types I and
III. Investigators have shown that a remodeling of these
collagens, mediated by the MMPs, may play a role in the
pathway leading to birth [42]. A spontaneous rupturing of
membranes before the completion of 37 weeks of gestation
is considered to be of pathological origin and is a leading
cause of PTB and delivery [43]. The MMPs are also believed
to play a major role in the remodeling of the uteroplacental
vasculature which changes throughout pregnancy [40].Obstetrics and Gynecology International 3
Several lines of investigation have implicated speciﬁc
MMPs in normal parturition as well as infection-triggered
rupture of membranes and preterm birth. A cross-sectional
study conducted by Maymon et al. [38] reported that, out
of 353 women involved, concentrations of MMP-1 were
detectable in 81.3% of amniotic ﬂuid samples, with the
concentrations increasing with gestational age. Additionally,
preterm PROM was associated with a signiﬁcant increase
in the median concentrations of amniotic MMP-1 in both
the presence and absence of infection, while term PROM
was not associated with an increase in MMP-1 levels [38].
Interestingly, Fujimoto et al. found that a polymorphism
resulting in increased MMP-1 promoter activity resulted
in an increased risk of preterm premature rupture of the
membranes [44]. In a cross-sectional study involving 365
subjects and conducted by Park et al. [45], increased levels
of MMP-3 were associated with parturition, both term and
preterm, as wells as microbial invasion of the amniotic
cavity.
Recently, much attention has been given to MMP-9,
also known as 92-kDa type IV collagenase or gelatinase
B[ 46]. MMP-9 is considered to be an enzyme which
plays a role in the latter part of ECM remodeling and,
unlike other MMPs, is produced and activated under certain
conditions such as infection, active labor, and premature
rupture of the membranes (PROM) [46, 47]. In the setting
of intraamniotic infection, the concentrations of AF MMP-9
and the inﬂammatory cytokine IL-6 have been found to be
signiﬁcantly elevated [39]. A study conducted by Harirah
et al. [39] reported that 22 out of 26 women with positive
AF cultures had detectable levels of MMP-9, ranging from
30.1 to 541.9ng/mL, while MMP-9 was nearly undetectable
in women with negative AF cultures. The MMP-9 cut-
oﬀ value used for predicting the presence or absence of
infection was 13.6ng/mL. In this study, spontaneous PTB
was not explored as an outcome because, for the majority
of women, the beneﬁts of inducing labor or having a
cesarean delivery outweighed those of going on with their
pregnancies.
In women with normal pregnancies, elevated levels of
MMP-9 have been found in the cervicovaginal ﬂuid and
are associated with cervical ripening before labor, but are
not a useful predictor for labor induction at term [48].
Under certain conditions, cervical ripening can be induced
by the inﬂammatory process which involves the catabolism
of the cervical ECM by enzymes discharged from inﬁltrating
leukocytes [49]. Watari et al. [49] reported that, in a dose-
dependent manner, the inﬂammatory cytokines TNF-α and
IL-1, which have been associated with PTB, produce an
increase in MMPs-1, -3, and -9 in a human uterine smooth
muscle system. Interestingly, these MMPs are the only ones
to have promoters that contain Activator Protein-1 and Ets-
binding sites [49].
While MMP-9 has been found to play a role in the events
associated with term and preterm labor, comparable changes
in MMP-2 protein levels and activity are often not reported.
This may suggest that MMP-2 is expressed continuously
throughout labor [46] while MMP-9 expression is induced
by various factors as previously mentioned. On the other
hand,Yonemotoetal.[37]havealsoreported,in2005,onthe
gestational age-dependant increases in MMP-2 proenzyme
activity and protein levels from the amnion in patients in
labor, suggestive of the induction of enzyme expression later
on in gestation. Moreover, Maymon et al. (2001) found a
decrease in tissue inhibitor of matrix metalloproteinase-2
(TIMP-2) in association with term and preterm parturition,
termandpretermruptureoffetalmembranes,andmicrobial
invasion of the amniotic cavity [50].
An increase in midtrimester concentrations of amniotic
ﬂuid MMP-8, IL-6, and angiogenin are risk factors for
early spontaneous preterm delivery (<32 weeks). MMP-
8 is released during neutrophil activation, and amniotic
ﬂuid concentrations are elevated both in patients with
intraamniotic infection and in patients with negative amni-
otic ﬂuid cultures who deliver preterm. Yoon et al. [51]
have developed a rapid MMP-8 bedside test that predicts
imminent preterm delivery. This test can be performed in 15
minutes and without laboratory equipment. In particular, an
elevated MMP-8 level of >23ng/mL is a powerful predictor
of spontaneous preterm delivery (<32 weeks). Amniotic
ﬂuid studies can be used to improve the risk assessment
for preterm delivery in women who undergo midtrimester
amniocentesis for genetic indications [51].
Even though some of the best clinical predictors for
PTL include cervical dilation >3cm, vaginal bleeding, and
ruptured membranes, these changes often appear too late
for successful intervention [52]. However, the detection
of plasma pro-MMP-9 levels and measurement of cervical
length in combination with cutoﬀ values of 65.157ng/mL
and 15mm, respectively, are characterized by 90.9% sensi-
tivity and 98.3% speciﬁcity and have been shown to possibly
function as predictive factors for PTB and PTL within 7 days
of presentation.
We have recently shown, using cDNA microarray tech-
nology, that several genes related to ECM homeostasis are
upregulated in placental chorionic villi from patients who
have labored as compared to patients who have undergone
Cesarean deliveries without labor [53]. In particular, we
found that MMP-1 was consistently elevated in placentas
from patients who had labored as compared to placentas
from patients who had not labored at both the mRNA and
protein level. Interestingly, the upregulation in MMP-1 was
seen in the fetal portion of the placenta, suggesting that the
fetus can contribute to its own premature expulsion from a
hostile intrauterine environment.
In 2007, we tested the nonspeciﬁc MMP inhibitor
GM6001 (EMD Biosciences, La Jolla, CA) for its eﬀect
on endotoxin-triggered preterm labor in a mouse model
[54]. GM6001 has Ki values for MMP-1, -2, -3, -8, and
-9 which are in the nanomolar-to-picomolar range. Brieﬂy,
pregnantC57Bl/6micewereinjectedwithLPSongestational
days 15.5–16 in order to simulate infection-associated PTB
and then received either GM6001 (study group) or vehicle
(control group) 12 hours later. In the GM6001 group there
was a signiﬁcant decrease in the number of mice delivering
prematurely when compared to the controls (Figure 1),
suggesting that one or more of the MMPs are critical in the
pathogenesis of infection-associated PTB.4 Obstetrics and Gynecology International
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Figure 1:EﬀectoftheMMPinhibitorGM6001onpretermdelivery
in the mouse model. (a) Incidence of preterm delivery in the mouse
model in either the absence (control group) or presence (study
group) of GM6001 after i.p. 3.3mg/kg LPS injection (P<. 01,
Fisher’s exact test). (b) Change in LPS injection-to-delivery time
intervalinhours,inthecontrolgroupversusstudygroup(P<. 005,
Mann-Whitney test).
4.The Endothelins
The human endothelin (ET) peptide family is made up
of three distinct isoforms—ET-1, ET-2, and ET-3 [55].
Composed of 21 amino acid residues with two sets of
intrachain disulﬁde linkages, the endothelins are produced
in an array of tissues with diﬀerent distribution patterns
andregulatevasomotortone,cellproliferation,andhormone
production [55–57].
Two types of ET receptors, Endothelin-A (ETA)a n d
Endothelin-B (ETB), have been identiﬁed in most mam-
malian species and belong to the superfamily of G-protein-
coupled receptors (GPCRs) [58]. Even though their amino
acid structures exhibit a signiﬁcant amount of similar
homology, the receptors have varying aﬃnities for the three
ET isoforms [58]. While the ETA receptor has a much greater
aﬃnity for ET-1 as compared to ET-2 and ET-3, the ETB
receptor binds all three members with equal aﬃnity [58].
ET-1 is the most potent vasoconstrictor in the ET family,
exhibiting a long duration of action, and is also the only
member to be produced in endothelial cells [56]. ET can
induce vasoconstriction via two major cell signaling systems:
the opening of calcium (Ca2+) channels and phospholipase-
Ca c t i v a t i o n[ 56]. Additionally, ET-1 is also produced by
a broad spectrum of cell types, including vascular smooth
muscle cells, hepatocytes, breast epithelial cells, and astro-
cytes of the central nervous system [59].
The 203-amino acid residue peptide precursor
preproendothelin-1 gives rise to ET-1 via the formation of
the 38- or 39- (species-dependent) amino acid intermediate
termed “big ET-1” which circulates in plasma [56].
Interestingly, big ET-1 is signiﬁcantly less potent than ET-1
in terms of inducing contractile actions in vascular strips,
but both forms are equally potent in raising blood pressure
in vivo [57].
Endothelin-converting enzyme-1 (ECE-1) is responsi-
ble for the cleaving of big ET-1 between the Trp21 and
Val22 residues, ultimately leading to the formation of ET-1
[56]. ET-1 is now implicated in an ever-growing list of
pathologic processes, ranging from pulmonary hypertension
to cancer. In particular, several lines of evidence support
the involvement of the peptide in obstetrical disorders. An
increase in maternal plasma ET-1 levels in patients with
preeclampsia was ﬁrst noted in 1990 [60]. Because the ETA
receptor has such a great aﬃnity for ET-1, the possible
therapeutic beneﬁt of selective ETA receptor antagonists
in preeclamptic women needs to be further explored.
Furthermore, ETA receptor-directed therapy may overlap
with antihypertensive management in preeclamptic patients.
The usefulness of this approach remains uninvestigated
[61].
Several investigators found that, in pregnant rats, a
chronicelevationintheserumlevelsofTNF-αandIL-6anda
reduction in uterine perfusion pressure lead to the activation
of the ET system [62, 63]. Romero et al. found higher human
amniotic ﬂuid concentrations of ET-1, -2 among women
who developed preterm labor and delivery and had culture-
proven microbial invasion of the amniotic cavity [64]a s
compared to uninfected women, suggesting a role for the
endothelins in infection-associated preterm birth. Mitchell
et al. reported that ET-1 regulates prostaglandin production
in human umbilical vein endothelial cells and cells derived
from the amnion and decidua [65].
We reported in 2004 that inhibition of endothelin-
converting enzyme-1 (ECE-1), which colocalizes with ET-1
in the placenta [66], controls PTD in a mouse model of
infection-associated PTL [67]. Subsequently, we have shown
that ECE-1 is upregulated in our mouse model of PTL and
that PTD is controlled with the ETA receptor antagonist
BQ-123 and with silencing of ECE-1 mRNA [68]( Figure 2).
Investigators have previously shown that, when com-
paredtoET-1,theresponsivenessoftheratuterustothecon-
tractileeﬀectsofET-3islessthan1%,suggestingthattheETA
receptor is responsible for modulating uterine contractions
[69]. Therefore, our group has recently developed a series ofObstetrics and Gynecology International 5
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Figure 2: Eﬀect of ET-1 blockade on preterm delivery in the mouse
model. (a) Incidence of preterm delivery in the mouse model in
the absence, presence of high-dose, or presence of low-dose BQ-123
(P<. 01 between control and high-dose groups, Fisher’s exact test).
(b) Eﬀect of SiRNA for ECE-1 in the animal model of infection-
associated PTB (P<. 001, Fisher’s exact test).
novel ETA receptor antagonists. We have shown that one of
ourcompounds, HJP-272, a 1,3, 6-trisubstituted-2-carboxy-
quinol-4-one (IC50, 70nmol/L), is capable of signiﬁcantly
decreasing the number of pups that are dropped prematurely
in the setting of infection [70].
While we do know that ET plays a very important role in
theinﬂammatorycascade-associatedinfection-inducedPTB,
the use of ETA receptor antagonists as a form of tocolytic
therapy remains controversial. Bosentan, often used in the
treatment of pulmonary hypertension, is a dual ET receptor
antagonist approved for use in the United States. While
the use of ET receptor antagonists may be useful for the
treatment of pulmonary hypertension, these agents are often
disregarded as potential tocolytics due to the fact that most
are pregnancy Category X drugs.
5. The LinkbetweenET-1 andthe MMPs
Recently, we have tested whether endothelin-1 and MMP-1
act in the same molecular pathway in our mouse model
of infection-associated preterm birth. We have shown that
MMP-1 is upregulated in placental and uterine tissues of
mice induced to preterm labor and delivery with LPS
(manuscript submitted for publication) and that the MMP
inhibitor GM6001 controls preterm birth in these same
animal models. We also compared levels of MMP-1 in LPS-
induced mice that were treated with RNAi directed at ECE-1
to levels of the protein in positive control LPS-induced
mice with unaltered ET-1 systems. We were interested to
ﬁnd that knocking down ET-1 synthesis knocked down
MMP-1 upregulation as well. Furthermore, those mice in
which ECE-1 and, consequently, MMP-1 levels were reduced
were largely prevented from developing preterm delivery
(manuscript submitted).
Several lines of investigation in other biologic sys-
tems have established that ET-1 aﬀects the synthesis of
MMPs. Koyama and Tanaka [71] have recently shown that
ET-1 stimulates the production of MMP-3 in cultured
rat astrocytes. Similarly, Manacu et al. [72] found that,
in primary cultures of human osteoarthritic chondrocytes,
the presence of ET-1 in the medium triggered increased
production of MMP-1 and MMP-13. Felx et al. [73]f o u n d
that ET-1 promotes induction of MMP-2 and MMP-9
in human osteosarcoma cells via the transcription factor
NF-κB. Furthermore, treatment of these malignant cells
with ET receptor antagonists decreases cell invasion. In
ET-1-activated human optic nerve head astrocytes, levels
of MMP-1, TIMP-1, and TIMP-2 are all increased. These
changes are mediated through the ERK map kinases and
protein kinase C [74]. ET-1 promotes cerebrovascular
remodeling in type 2 diabetes through diﬀerential regulation
ofMMPs[75].Murrayetal.[76]producedamarkedincrease
in MMP-2 activity and a signiﬁcant decrease in collagen
volume fraction in rat hearts by administering ET-1. More
recently, they have shown that rats that underwent the
surgical introduction of an aortocaval ﬁstula had much less
of a change in MMP-2 levels and in collagen volume fraction
oftheheartiftheyweretreatedwithBosentan,anendothelin
receptorantagonist[77].Interestingly,Leeetal.reportedthat
vascular endothelial growth factor- (VEGF-) induced ET-1
production occurs via MMP-2 action, and independently of
ECE-1 function [78]. Finally, Deschamps et al. [79] showed
thattheincreaseinMMP-1levelsinporcineheartsassociated
with ischemia and reperfusion injury did not occur if the
animals were treated with the ET-1 receptor-A antagonist
BQ-123.
6. Conclusion
Increased levels of inﬂammatory cytokines in the setting of
infectionultimatelyleadtoPTLandPTBviaseveraldiﬀerent
mechanisms and feedback loops which occur at the maternal
fetalinterface.SeverallinesofevidenceindicatethatbothET-
1 and the MMPs are critical parts of the molecular pathway
that connects ascending bacterial infection to PTB. A simple6 Obstetrics and Gynecology International
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Endothelin-1
Prostaglandins
Matrix metalloproteases
Preterm labor
Cytokines (TNF, IL-1, -6, -8)
Figure 3: Parturition cascade with putative sites of action of
endothelin-1 and matrix metalloproteinases.
skeletal version of the parturition cascade, including the
putative sites of activity of ET-1 and the MMPs, is shown
in Figure 3. On one hand, the risk of teratogenicity caused
by any potential tocolytic agent is minimized, because
the period of administration is transient, and because the
agent would be given well after organogenesis is complete.
On the other hand, as both endothelin and the MMPs
play a role in embryonic and fetal development, agents
blocking the actions of either of these important molecular
players are somewhat suspect for potential fetal toxicity.
A better understanding of the infection-associated preterm
labor molecular pathway is needed, so that more and more
potential targets for therapy can be revealed.
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